About Cyfuse
Cyfuse is a company based in Bunkyo (Japan) founded in 2010. Cyfuse has raised $16.56 million across 2 funding rounds from investors including Shibuya Kogyo, m3.com and Cyberdyne. The company has 21 employees as of December 31, 2024. Cyfuse operates in a competitive market with competitors including Nuclera Nucleics, CELLINK, Aspect Biosystems, OxSyBio and Collplant, among others.
- Headquarter Bunkyo, Japan
- Employees 21 as on 31 Dec, 2024
- Stage Public
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cyfuse Biomedical K.K.
-
Annual Revenue
$346.93 K (USD)-10.91as on Dec 31, 2024
-
Net Profit
-$5.56 M (USD)-48.03as on Dec 31, 2024
-
EBITDA
-$5.48 M (USD)-30.46as on Dec 31, 2024
-
Total Equity Funding
$16.56 M (USD)
in 2 rounds
-
Latest Funding Round
$11.76 M (USD), Series B
Feb 27, 2015
-
Investors
Shibuya Kogyo
& 11 more
-
Employee Count
21
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Cyfuse
Cyfuse is a publicly listed company on the TSE with ticker symbol 4892 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Cyfuse
Cyfuse has successfully raised a total of $16.56M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $11.76 million completed in February 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cyfuse
Cyfuse has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Shibuya Kogyo, m3.com and Cyberdyne.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Seed and Early stage VC firm investing in Japan
|
Locked | Locked | Locked | |
|
Venture capital services are provided to support startups and innovation.
|
Locked | Locked | Locked | |
|
Venture capital investments are provided to innovative startups by DBJ Capital.
|
Locked | Locked | Locked |
Investor details for Cyfuse
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cyfuse
Investment portfolio details for Cyfuse
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cyfuse
Detailed financials for Cyfuse
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cyfuse Comparisons
Peer comparison for Cyfuse
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cyfuse
Cyfuse operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nuclera Nucleics, CELLINK, Aspect Biosystems, OxSyBio and Collplant, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Desktop bioprinter for genes and proteins production is developed.
|
|
| Locked | Locked | Locked |
3D bioprinters and bioinks are developed for research applications.
|
|
| Locked | Locked | Locked |
Bioprinting technology and tissue therapeutics for regenerative medicine are developed.
|
|
| Locked | Locked | Locked |
Provider of 3D printing of tissue biomaterials for medical research and clinical applications
|
|
| Locked | Locked | Locked |
Plant-derived collagen is developed for tissue repair and 3D bioprinting.
|
|
| Locked | Locked | Locked |
Developer of integrated 3D printing and tissue-engineering platform
|
Detailed competitors of Cyfuse
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cyfuse
Complete news archive for Cyfuse
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cyfuse
Cyfuse was founded in 2010 and raised its 1st funding round 3 years after it was founded.
Cyfuse is headquartered in Bunkyo, Japan. It is registered at Bunkyo, Tokyo, Japan.
Shizuka Akieda is the current CEO of Cyfuse.
Cyfuse is a funded company, having raised a total of $16.56M across 2 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Cyfuse is 21.
Annual revenue of Cyfuse is $346.93K as on Dec 31, 2024.
Founded in 2010 and based in Bunkyo, Japan, Cyfuse focuses on the biotechnology sector through 3D bioprinters. The Regenova system is utilized for producing three-dimensional tissues and organs, while the Spike device is employed to assemble spheroids into custom shapes. These tools support advancements in regenerative medicine and drug discovery processes. Operations emphasize automated fabrication to aid research and development in tissue engineering.
Cyfuse's top competitors include Nuclera Nucleics, Aspect Biosystems and Collplant.
Yes, Cyfuse is publicly traded on TSE under the ticker symbol 4892.
Cyfuse has 12 investors. Key investors include Shibuya Kogyo, m3.com, Cyberdyne, UT-EC Japan, and JAFCO Group.
The ticker symbol of Cyfuse is 4892 on TSE.